Cutaneous amoebiasis is an extraintestinal manifestation of amoebic infection. When patients are unable to tolerate or absorb oral medication — or when disease is severe — parenteral treatment becomes the appropriate route of management.
This protocol is indicated for patients with cutaneous amoebiasis presenting with severe disease or in whom oral therapy is not feasible due to intolerance or impaired absorption.
Management begins with intravenous nitroimidazole therapy. Because nitroimidazoles alone do not effectively eradicate luminal cysts, initial IV treatment must be followed by a luminal cysticidal agent. Several options exist for the luminal phase; the complete sequence, agent selection, and criteria are in the full protocol.
DOI: 10.1093/ofid/ofy161
In patients who are unable to tolerate or absorb oral metronidazole, intravenous metronidazole should be used.
Severe disease or unable to tolerate oral therapy, use metronidazole 1500 mg IV divided TID (7.5–30 mg/kg/d divided TID).
The nitroimidazoles do not effectively eradicate luminal cysts and must be followed by a luminal agent.
View source ↗